We found that the inflammation unfortunately gets hijacked by
tumor cells that are able to grow faster and
penetrate deeper because the blood vessels in the
brain are more permeable than in any other part of the body.
Genetically modified «hunter» T
cells successfully migrated to and
penetrated a deadly type of
brain tumor known as glioblastoma (GBM) in a clinical trial of the new therapy, but the
cells triggered an immunosuppressive
tumor microenvironment and faced a complex mutational landscape that will need to be overcome to better treat this aggressive cancer, Penn Medicine researchers report in a new study this week in Science Translational Medicine.